Consensus Inhibikase Therapeutics, Inc.

Equities

Delayed Nasdaq Other stock markets 10:12:33 2024-05-17 EDT			5-day change	1st Jan Change
1.8 ^USD	+2.28%		+37.41%	+41.74%

05-16	Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
05-09	Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	CI

1.4FGmFYMJGDsoPln9ti5jaoWyvGPZgHh3ftNafVqCPTs.lAnITLdjYWEaXDDMghcmAeTRxDD00z8fMaZtGTS7WG6iYc937EJ_V0pnbQ~4bed5393c1d39b01dbb630430919f030

Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8	02-20	MT
HC Wainwright Starts Inhibikase Therapeutics at Buy With $5 Price Target	23-04-18	MT
JonesTrading Downgrades Inhibikase Therapeutics to Hold From Buy	22-11-16	MT
INHIBIKASE THERAPEUTICS : JonesTrading Initiates Inhibikase Therapeutics at Buy Rating With $12 Price Target	21-07-15	MT
DJ Industrial : US Stocks Drop After Some FOMC Members Signal Earlier Rate Hikes	21-06-16	MT
Close Update: US Stocks Decline as Fed Projects Rate Hike Implementation in 2023	21-06-16	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.76 USD

Average target price

17.5 USD

Spread / Average Target

+894.32%

High Price Target

27 USD

Spread / Highest target

+1,434.09%

Low Price Target

8 USD

Spread / Lowest Target

+354.55%

Maxim
HC Wainwright
JonesTrading Institutional Services